ViiV’s new capsid inhibitor demonstrated promising phase IIa data, with oral doses ranging from 25 mg to 250 mg every five days in ART-naïve individuals. By day 11, virologic suppression was observed. The drug is planned for development as an injectable long-acting (LA) therapy. The chemical structure of VH4011499 is not available in the public domain. Similarly, no patent information is available yet, however patent filings are to be expected.